National Institute of Allergy and Infectious Diseases (NIAID) Archives

NIH to study allergic reactions to COVID-19 mRNA vaccine

Image courtesy of Pexels

Researchers from the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) are conducting a clinical trial on allergic reactions to mRNA-based COVID-19 vaccines.

The single-site trial will enroll up to 100 people between 16 and 69 years old who had an allergic reaction to a first dose of COVID-19 mRNA vaccines. NIAID seeks participants who experienced a mild or moderate systemic allergic reaction to either the Pfizer/BioNTech or Moderna COVID-19 vaccines.

Get the full story at our sister site, Drug Discovery & Development.

NIH to study allergic reactions to COVID-19 mRNA vaccine

Photo from Pexels

Researchers from the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) are conducting a clinical trial on allergic reactions to mRNA-based COVID-19 vaccines.

The single-site trial will enroll up to 100 people between 16 and 69 years old who had an allergic reaction to a first dose of COVID-19 mRNA vaccines. NIAID seeks participants who experienced a mild or moderate systemic allergic reaction to either the Pfizer/BioNTech or Moderna COVID-19 vaccines.

People who developed a severe allergic reaction to a first dose of a COVID-19 mRNA vaccine are not eligible to enroll.

According to a news release, participants will receive a second dose of the vaccine as inpatients under carefully controlled conditions at the National Institutes of Health’s Clinical Center in Bethesda, Maryland. NIAID’s Laboratory of Allergic Diseases’ Dr. Pamela A. Guerrerio…

NIH launches study of allergic reactions to COVID-19 vaccines

(Image by Sam Moqadam on Unsplash)

The NIH today announced that a clinical trial is underway to study whether people who are highly allergic or have a mast cell disorder are more likely to develop an allergic reaction to the Moderna or Pfizer-BioNTech COVID-19 vaccines.

Reports of severe allergic reactions to COVID-19 vaccines have made headlines since the rollout to the public began. Still, such anaphylactic reactions are rare, with only a few cases per million doses. To put things in perspective, tens of thousands of Americans end up in emergency rooms annually with severe allergic reactions.

The NIH’s National Institute of Allergy and Infectious Diseases is sponsoring and funding the news study, which is enrolling 3,400 adults ages 18 to 69 years at up to 35 academic allergy-research centers nationwide.

Get the full story on our sister site Drug Discovery & Development.

NIH launches study of allergic reactions to COVID-19 vaccines

[Image by Sam Moqadam on Unsplash]

The NIH today announced that a clinical trial is underway to study whether people who are highly allergic or have a mast cell disorder are more likely to develop an allergic reaction to the Moderna or Pfizer-BioNTech COVID-19 vaccines.

Reports of severe allergic reactions to COVID-19 vaccines have made headlines since the rollout to the public began. Still, such anaphylactic reactions are rare, with only a few cases per million doses. To put things in perspective, tens of thousands of Americans end up in emergency rooms annually with severe allergic reactions.

Most of the rare, severe allergic reactions to the vaccines took place among people with a history of allergies — many of them with prior experience of having a life-threatening allergic reaction called anaphylaxis. Researchers are still uncertain why there are rare cases of anaphylactic reactions after the Mode…

NIAID expresses concern over AstraZeneca’s COVID-19 vaccine data

The National Institute of Allergy and Infectious Diseases (NIAID) has announced concerns with data from AstraZeneca’s COVID-19 vaccine trial.

NIAID, a wing of the National Institutes of Health (NIH), said in a statement today that it was concerned after information released by the company surrounding the clinical trial for its AZD1222 vaccine may be outdated. In turn, that may have provided an incomplete view of the efficacy data, NIAID said.

Get the full story at our sister site, Drug Discovery & Development.

NIAID expresses concern over AstraZeneca’s COVID-19 vaccine data

The National Institute of Allergy and Infectious Diseases (NIAID) has announced concerns with data from AstraZeneca’s COVID-19 vaccine trial.

NIAID, a wing of the National Institutes of Health (NIH), said in a statement today that it was concerned after information released by the company surrounding the clinical trial for its AZD1222 vaccine may be outdated. In turn, that may have provided an incomplete view of the efficacy data, NIAID said.

“We urge the company to work with the [Data and Safety Monitoring Board (DSMB)] to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible,” NIAID wrote in the statement.

AstraZeneca yesterday published results from the trial, revealing that the vaccine developed in collaboration with Oxford University was 79% effective in preventing symptomatic COVID-19 and 100% effective in preventing severe disease and hospitalization.

Buoyed b…

Abbott researchers help discover a clue to an HIV cure

Scanning electron micrograph of HIV-1 (in green) budding from cultured lymphocyte. [Image courtesy of CDC]Abbott announced today that a team including its scientists has uncovered a rare group of Democratic Republic of Congo residents who are HIV positive but have almost nonexistent viral loads without using antiretroviral treatments.

This group of “HIV elite controllers” opens up a new area for researchers to discover biological trends that could inform the creation of better HIV treatments and potential vaccines.

The researchers from Abbott, Johns Hopkins University, the National Institute of Allergy and Infectious Diseases, the University of Missouri-Kansas City and the Université Protestante au Congo found that the prevalence of HIV elite controllers was 2.7–4.3% in the DRC, versus 0.1–2% worldwide.

Get the full story on our sister site Drug Discovery & Development.

Abbott researchers help discover a clue to an HIV cure

Scanning electron micrograph of HIV-1 (in green) budding from cultured lymphocyte. [Image courtesy of CDC]

Abbott announced today that a team including its scientists has uncovered a rare group of Democratic Republic of Congo residents who are HIV positive but have almost nonexistent viral loads without using antiretroviral treatments.

This group of “HIV elite controllers” opens up a new area for researchers to discover biological trends that could inform the creation of better HIV treatments and potential vaccines.

The researchers from Abbott, Johns Hopkins University, the National Institute of Allergy and Infectious Diseases, the University of Missouri-Kansas City and the Université Protestante au Congo found that the prevalence of HIV elite controllers was 2.7–4.3% in the DRC, versus 0.1–2% worldwide.

The group published their findings today in EBioMedicine (part of The Lancet). Read more

What are the top COVID-19 vaccine candidates?

This colorized scanning electron microscope image shows SARS-CoV-2 (round blue objects), the virus that causes COVID-19, emerging from the surface of cells cultured in the lab. [Image courtesy of National Institute of Allergy and Infectious Diseases]

As of yesterday, five COVID-19 vaccine candidates had begun Phase III clinical trials as they seek to determine the safety and efficacy of their formulas.

Researchers worldwide are testing 132 COVID-19 vaccine candidates, including 42 that are in clinical trials on humans and at least 92 in preclinical or animal trials, according to the New York Times.

With the U.S. alone topping 200,000 COVID-19 deaths this week and continued pressure to deliver a safe and effective vaccine, these companies and several others are working very quickly to make a vaccine that meets regulatory standards. Seven pharma companies have received funding for vaccine development and…